back

PRESS RELEASE

United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2019 financial results before the market opens on Wednesday, July 31, 2019.

United Therapeutics will host a teleconference on Wednesday, July 31, 2019, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 3066089.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm. [uthr-g]

View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-second-quarter-2019-financial-results-before-the-market-opens-on-wednesday-july-31-2019-300889819.html

SOURCE United Therapeutics Corporation

Recent Press Releases

09 Mar 2026

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next yearSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS...

Download pdf

03 Mar 2026

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr.Martine Rothblatt,Chairperson and Chief Executive Officer, will provide a...

Download pdf

02 Mar 2026

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly pre-treated patients with...

Download pdf

25 Feb 2026

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended...

Download pdf

23 Feb 2026

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz,President and Chief Operating Officer, will provide a company...

Download pdf

11 Feb 2026

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before...

Download pdf

view all